Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03955250
Other study ID # 1905-001
Secondary ID R34MH115144
Status Completed
Phase N/A
First received
Last updated
Start date May 31, 2019
Est. completion date May 31, 2022

Study information

Verified date February 2024
Source Butler Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aim of this program of research is to refine and test the feasibility and acceptability of a newly developed mobile device-delivered app, called Mobile After-Care Support (MACS), to improve patients' coping and treatment adherence following a hospitalization related to their psychotic-spectrum disorder. The purpose of the proposed project is to establish the feasibility, acceptability, and preliminary effects of the app. To achieve the specific aims, the investigators will conduct a pilot randomized clinical trial (n = 60), with two treatment arms: MACS vs. a mobile app attention control condition.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date May 31, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - recently hospitalized - DSM-5 criteria for psychotic-spectrum disorder based on structured clinical interview - 18 years or older - prescribed antipsychotic medication upon discharge - ability to speak and read English Exclusion Criteria: - substance use disorders at severe level - planned discharge to supervised living setting or participation in formal outpatient adherence programs - pregnancy or other medical condition contraindicating use of antipsychotic medications

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mobile After-Care Support (MACS) app
The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
Mobile app attention control
The control app provides ecological momentary assessment and psychoeducation about illness.

Locations

Country Name City State
United States Butler Hospital Providence Rhode Island

Sponsors (2)

Lead Sponsor Collaborator
Butler Hospital National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Client Satisfaction Questionnaire (CSQ) The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment. 1 month
Secondary Brief Psychiatric Rating Scale (BPRS) The interviewer-rated Brief Psychiatric Rating Scale is a measure of psychiatric symptom severity. The total score (sum of items) will be used to assess overall severity with scores ranging from 18 to 126 and higher scores indicating greater severity. Baseline, 4 month
Secondary Brief Adherence Rating Scale (BARS) The Brief Adherence Rating Scale assesses the percentage of missed medication doses over the past month. The total adherence score ranges from 0% to 100% and higher scores indicate greater adherence. Baseline, 4 month
Secondary Brief Cope Inventory (Brief COPE) The Brief Cope Inventory is a 28 item self-report measure of coping skills. The mean values of the 12-item dysfunctional coping subscale was used. Mean scores for the total range from 1-48 with higher scores indicating greater use of the dysfunctional coping strategies. Baseline, 4 month
See also
  Status Clinical Trial Phase
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Active, not recruiting NCT00627029 - Evaluation of Programs of Coordinated Care and Disease Management N/A
Terminated NCT00049738 - Screening for Childhood-Onset Psychotic Disorders N/A
Withdrawn NCT01724372 - The Role of Antidepressants or Antipsychotics in Preventing Psychosis N/A
Completed NCT00716755 - Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. N/A
Completed NCT00498550 - Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Phase 4
Terminated NCT04140773 - The Effect of D-serine as add-on Therapy in Recent-onset Psychosis N/A
Completed NCT01473550 - Mental Health Engagement Network (MHEN) N/A
Completed NCT01207219 - Yoga and Aerobic Exercise in Psychosis N/A
Completed NCT00397033 - Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder. Phase 3
Recruiting NCT04945278 - Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability N/A
Completed NCT00287352 - Study of Amantadine for Weight Stabilization During Olanzapine Treatment Phase 1
Completed NCT00005658 - Glycine to Treat Psychotic Disorders in Children Phase 2
Terminated NCT00169026 - Alcoholism and Schizophrenia: Effects of Clozapine Phase 4
Completed NCT00001482 - New Drugs in the Treatment of Mood Disorders Phase 2
Terminated NCT03671005 - Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders N/A
Completed NCT00156715 - Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Phase 4
Completed NCT00095524 - Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder Phase 3
Completed NCT03667729 - The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia N/A
Completed NCT00001656 - Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders Phase 4